Lonza has expanded its collaboration with Moderna to manufacture the drug substance for the biopharma’s COVID-19 vaccine.   The expanded collaboration provides for the installation of three additional drug substance manufacturing lines at Lonza’s Visp, Switzerland site. This will double the existing drug substance production for COVID-19 Vaccine Moderna at the site.   In May 2020, Lonza and Moderna entered a 10-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-1...